Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Depreciation & Amortization (CF) (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Depreciation & Amortization (CF) data on record, last reported at $461000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 9.61% year-over-year to $461000.0; the TTM value through Sep 2025 reached $1.9 million, down 53.82%, while the annual FY2024 figure was $3.4 million, 20.27% down from the prior year.
  • Depreciation & Amortization (CF) reached $461000.0 in Q3 2025 per TNXP's latest filing, down from $483000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.3 million in Q4 2023 and bottomed at $461000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 3 years is $831727.3, with a median of $893000.0 recorded in 2023.
  • The widest YoY moves for Depreciation & Amortization (CF): up 35.5% in 2024, down 60.67% in 2024.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $1.3 million in 2023, then tumbled by 60.67% to $496000.0 in 2024, then decreased by 7.06% to $461000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $461000.0 in Q3 2025, $483000.0 in Q2 2025, and $493000.0 in Q1 2025.